SCHEMBL57101

SCHEMBL57101

O=C(Oc1ccc(Br)cc1)Oc1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LDHA P00338 1/20 0.50
MAPT P10636 3/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
MGLL Q99685 1/20 0.44
CHRNA7 P36544 1/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 1/20 0.43
CYP2A6 P11509 1/20 0.42
NCEH1 Q6PIU2 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638842 0.93 MEN1 (0.45) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL6321010 0.91 LDHA (0.48) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL6255843 0.89 PPARA (0.49) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL24419014 0.86 KMT2A (0.52) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL16192959 0.84 F2 (0.45) MEN1KMT2ARAB9AMGLLRXRA
SCHEMBL17637680 0.84 TP53 (0.52) MEN1KMT2ALMNAMAPK1RAB9A
SCHEMBL11013322 0.82 LMNA (0.42) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL3504737 0.82 LDHA (0.54) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL9671509 0.82 LDHA (0.48) MEN1KMT2ALDHAMAPTLMNA
SCHEMBL22228973 0.81 MGLL (0.41) MEN1KMT2ALDHAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572728-B1 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF MOUNTAIN VIEW PHARMACEUTICALS (US) 2014-06-25 EP claimed
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2012-05-10 US claimed
US-8129330-B2 Complex of polyoxyethylene glycol with active material MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2012-03-06 US claimed
EP-1560871-B1 METHOD FOR MAKING COPOLYCARBONATES GEN ELECTRIC (US) 2006-10-11 EP claimed
JP-2006510601-A 2006-03-30 JP claimed
EP-1572728-A2 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF Mountain View Pharmaceuticals, Inc. (US) 2005-09-14 EP claimed
EP-1560871-A1 METHOD FOR MAKING COPOLYCARBONATES GENERAL ELECTRIC COMPANY (US) 2005-08-10 EP claimed
EP-1421175-A4 POLYMER STABILIZED PROTEINASES MOUNTAIN VIEW PHARMACEUTICALS (US) 2004-12-08 EP claimed
EP-1421175-A2 POLYMER STABILIZED PROTEINASES Mountain View Pharmaceuticals, Inc. (US) 2004-05-26 EP claimed
WO-2004041907-A1 METHOD FOR MAKING COPOLYCARBONATES GENERAL ELECTRIC COMPANY (US) 2004-05-21 WO claimed
WO-2004030617-A2 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2004-04-15 WO claimed
US-20040062748-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. 2004-04-01 US claimed
US-20040062746-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. 2004-04-01 US claimed
US-6657038-B1 Melt condensation copolymerization of dihydroxyaromatic compounds and diphenyl carbonate derivative in presence of metal hydroxide and quaternary phosphonium salt GENERAL ELECTRIC COMPANY 2003-12-02 US claimed
US-20030012777-A1 Polymer conjugates of proteinases MOUNTAIN VIEW PHARMACEUTICALS, INC. 2003-01-16 US claimed
WO-2003002716-A2 POLYMER STABILIZED PROTEINASES MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2003-01-09 WO claimed
CN-122095024-A Flame-retardant aromatic polycarbonate resin composition and molded article thereof 2026-05-26 CN disclosed
WO-2026100296-A1 FLAME-RETARDANT AROMATIC POLYCARBONATE RESIN MASTER BATCH AND METHOD FOR MANUFACTURING SAME 信越化学工業株式会社 2026-05-15 WO disclosed
US-3945967-A ALKYL PHOSPHITE, EPOXY COMPOUND GENERAL ELECTRIC COMPANY (US) 1976-03-23 US disclosed
US-3933730-A POLYDIMETHYLSILOXANE GUM, DIVIDED SILICA GENERAL ELECTRIC COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040062748-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof CD14, HLA-C, HLA-A MEN1 1245/4885KMT2A 2567/4885LDHA 2217/4885
US-20040062746-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof CD14, HLA-C, HLA-A MEN1 1245/4885KMT2A 2567/4885LDHA 2217/4885
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof CD14, HLA-C, HLA-A MEN1 1245/4885KMT2A 2567/4885LDHA 2217/4885
US-20030012777-A1 Polymer conjugates of proteinases PRNP, PRSS3, PRSS1 MEN1 4007/4885KMT2A 2115/4885LDHA 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.